TriLink BioTechnologies社 mRNA Vaccines - A New Era in Vaccinology
 |
|
|
|
mRNA Vaccines – A New Era in Vaccinology |
|
mRNA vaccines, propelled into public view in 2020 by their development for COVID-19, have actually had a relatively prolonged incubation period. While the first evidence for an mRNA vaccine dates back to a report by Martinon et al. in 1993, subsequent scientific progress was slow in the NIH’s PubMed database. More specifically, these articles did not appear until 2004 (Pascolo and collaborators; Cannon and Weissman), were followed by one in 2010 (Weiss et al.), and then several more per year until about 2015, when the number of annual reports noticeably increased...
Your Partner for mRNA Vaccine Development
The recent clinical success of mRNA vaccines against SARS-CoV-2 paves the way for future vaccine development. Whether you are in the discovery phase or nearing GMP manufacturing, TriLink offers a solution to fit your mRNA vaccine program: |
|
|
· Plasmid manufacturing for use as an IVT template · Custom mRNA synthesis from RUO through GMP grade
· CleanCap® capping technology for non-replicating mRNA and self-amplifying mRNA Learn more about how TriLink can support your vaccine development program. |
 |
 |
|
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。
